FKS与光滑念珠菌棘白菌素耐药

中国真菌学杂志　 2014, Vol. 9 　Issue (6): 364-367,363.

FKS与光滑念珠菌棘白菌素耐药

高盈, 佘晓东, 刘维达

北京协和医学院中国医学科学院皮肤病研究所真菌科, 南京 210042

收稿日期:2014-06-27 出版日期:2014-12-28 发布日期:2014-12-28
通讯作者: 刘维达,E-mail:liumyco@hotmail.com E-mail:liumyco@hotmail.com
作者简介:高盈,女 (汉族),博士研究生在读.E-mail:nanjingpys2013@126.com
基金资助:
国家973项目 (2013CB531605);江苏省自然基金青年基金 (BK20130063)

Advances in research on FKS mutation and echinocandin resistance of Candida glabrata

GAO Ying, SHE Xiao-dong, LIU Wei-da

Department of Mycology, Institute of Dermatology, Chinese Academy of Medical Science＆Peking Union Medical College, Nanjing 210042, China

Received:2014-06-27 Online:2014-12-28 Published:2014-12-28

摘要/Abstract

摘要： 近年来,光滑念珠菌侵入性感染及其耐棘白菌素治疗失败的病例不断增多,深入研究其耐药机制十分有必要。Fks突变在光滑念珠菌棘白菌素耐药发生的过程中有着极其重要的地位,其与棘白菌素的MIC值及体内治疗结果密切相关,且有很多因素可以对Fks突变的发生及其作用产生影响。

关键词: 光滑念珠菌, Fks突变, MIC, 棘白菌素耐药

Abstract: The proportion of systemic fungal infections in humans caused by C.glabrata has increased significantly in recent years, and in the same time, cases about echinocandins therapeutic failure to this pathogen has been reported more and more.FKS mutation has a significant role in the growth of MIC values and echinocandin resistance, and a lot of elements can effect it.

Key words: Candida glabrata, Fks mutation, MIC, echinocandins resistance

中图分类号:

R379.4

高盈, 佘晓东, 刘维达. FKS与光滑念珠菌棘白菌素耐药[J]. 中国真菌学杂志, 2014, 9(6): 364-367,363.

GAO Ying, SHE Xiao-dong, LIU Wei-da. Advances in research on FKS mutation and echinocandin resistance of Candida glabrata[J]. Chinese Journal of Mycology, 2014, 9(6): 364-367,363.

参考文献

[1] Arendrup MC.Epidemiology of invasive candidiasis[J].Curr Opin Crit Care,2010,16(5):445-452.
[2] Katiyar SK,Alastruey-Izquierdo A,Healey KR,et al.Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata:implications for echinocandin resistance[J].Antimicrobial and chemotherapy,2012,12(56):6304-6309.
[3] Alexander BD,Johnson MD,Pfeiffer CD,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clinical Infectious Disease,2013,56(12):1724-1732.
[4] Castanheira M,Woosley LN,Pfaller MA,et al.Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp[J].Antimicrobial and chemotherapy,2010.,54(6):2655-2659.
[5] Walker LA,Gow NA,Munro CA.Fungal echinocandin resistance[J].Fungal Genet Biol,2010,47(2):117-126.
[6] Cowen LE.The evolution of fungal drug resistance:modulating the trajectory from genotype to phenotype[J].Nat Rev Microbiol,2008,6(3):187-198.
[7] Park,S,R.Kelly,N.Kahn,et al.Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp Isolates[J].Antimicrob Agents Chemother,2005,49(8):3264-3273.
[8] Garcia-Effron,G,S.Lee,S.Park,et al.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3- -D-glucan synthase:implication for the existing susceptibility breakpoint[J].Antimicrob Agents Chemother,2009,53(9):3690-3699.
[9] Nicholas D.Beyda,Julie John,Abdullah Kilic,et al.FKS mutant Candida glabrata;risk factors and outcomes in patients with candidemia[J].Clinical Infectious Diseases,2014,59(6):819-825.
[10] Mariana Castanheira,Leah N.Woosley,et al.Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates[J].Antimicrob Agents Chemother,2014,58(1):577.
[11] Zimbeck AJ,Iqbal N,Ahlquist AM,et al.FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S.population-based surveillance[J].Antimicrob Agents Chemother,2010,54(12):5042-5047.
[12] Pham CD,Iqbal N,Bolden CB,et al.The role of FKS mutations in C.glabrata:MIC values,echinocandin resistance and multidrug resistance[J].Antimicrob Agents Chemother,2014 58(8):4690-4696.
[13] Sheen a D.Singh-Babak,Tomas Babak,Stephanie Diezmann,et al.Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata[J].PLOS Pathogens,2012,8(5):1-23.
[14] Lepak A,Castanheira M,Diekema D,et al.Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations[J].Antimicrob Agents Chemother,2012,56(11):5875-5882.
[15] Fabiola Fernandez-Silva,Michaela Lackner,Javier Capilla,et al.In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection[J].Antimicrob.Agents Chemother,2014,58(7):3646-3649.
[16] Arendrup MC,Perlin DS,Jensen RH,et al.Differential in vivo activities of anidulafungin,caspofungin,and micafungin against 458 Candida glabrata isolates with and without FKS resistance mutations[J].Antimicrob.Agents Chemother,2012,56(5):2435-2442.
[17] Andes D,Diekema DJ,JPfaller MA,et al.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species[J].Antimicrob Agents Chemother,2010,54(6):2497-2506.
[18] Pappas PG,et al.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis[J].Clin.Infect Dis,2007,45(7):883- 893.
[19] Shields RK,Nguyen MH,Press EG,et al.2012.The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Antimicrob[J].Agents Chemother,2012,56(9):4862-4869.
[20] Pfeiffer CD,Garcia-Effron G,Zaas AK,et al.Breakthrough invasive candidiasis in patients on micafungin[J].Clin Microbiol,2010,48(7):2373-2380.
[21] Kyoko Niimi,Matthew A.Wood,Katsuyuki maki,et al.Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression[J].Antimicrob Chemother,2012,67(7):1666 -1676.